18 January 2023 in Journal of Primary Care & Community Health
Introduction/Objectives: Telehealth services expanded during the coronavirus disease 2019 (COVID-19) pandemic. Student-run free clinics (SRFC) deliver important health care services to underserved populations, who may face barriers to telehealth use. This study characterizes telehealth usage, experiences, and attitudes among individuals working in SRFCs. Methods: In November 2021, a survey adapted from the COVID-19 Healthcare Coalition Telehealth Impact Physician Survey was sent to all registrants who identified themselves as students at the 2020 Society of Student-Run Free Clinics Annual Conference. Results: Thirty-eight individuals of 576 registrants (7%) representing 21 of 88 (24%) SRFCs completed the survey. Twenty-one (58%) individuals reported using telehealth in their clinic. Those that did not cited lack of infrastructure as a barrier (eg, broadband, Internet challenges, technology investments), were more likely to serve homeless (P = .01), and less likely to serve non-English speaking populations (P = .02). There were increases in telehealth and decreases in in-person visits after March 11, 2020 though changes did not reach statistical significance. At least 15 (68%) wanted to continue chronic disease management, preventative care, and mental/behavioral health via telehealth after COVID-19. Most felt that telehealth was easy to use and improved the health, safety, and timeliness of care of patients, but not work satisfaction or access to care. Difficulty accessing physical devices, Internet, and data was the most-cited barrier to maintaining and accessing telehealth. Conclusions: Nearly all participants cited significant benefits and barriers to telehealth that impacted perceived access to care and sustainability. SRFCs’ experiences may be modulated by their underserved populations and role in student education. Addressing barriers, particularly patient- and clinic-level technology challenges, could work to improve inequities in telehealth uptake.
27 April 2024 in Facial Plastic Surgery
Facial feminization surgery (FFS) improves gender dysphoria. The brows and eyes are crucial in perceived gender, yet brow and eyelid surgeries are relatively underutilized. This study aimed to determine rates of brow and eyelid surgeries as part of FFS and characterize pre- and postoperative periocular features. We conducted a retrospective review to identify all patients with the diagnosis of gender dysphoria who underwent FFS at a single academic institution from 2019 to 2022. Thirty-four patients comprising 38 surgical cases were included. Twelve (35%) eyelid surgeries and 27 (79%) brow lifts were performed. Baseline eyelid measurements did not differ between brow lift and nonbrow lift cases. Those undergoing brow lift and eyelid surgery were older in age (p = 0.022), had a higher rate of negative canthal tilt (p = 0.050), and smaller baseline margin-reflex distance 1 (p = 0.014) than patients who had brow lift alone. Brow lift increased tarsal platform show (p ≤ 0.001) and lash-to-brow distance (p ≤ 0.001), and upper blepharoplasty increased tarsal platform show (p = 0.01). Rates of brow lift are high at our institution, and patients are appropriately selected for eyelid surgery in FFS. Brow lift and upper blepharoplasty can feminize anatomical features when using standards described for cisgender cohorts. The impact of periocular features on gender perception in transgender patients warrants further study.
10 April 2022 in Seminars in Ophthalmology
To perform a retrospective characterization of one-star reviews of ophthalmologists on Yelp.com and to increase understanding of patient complaints on Yelp.com.A search was performed for reviews on...
28 June 2023 in Journal of NeuroInterventional Surgery
Background Melphalan, which is poorly soluble at room temperature, is widely used for the treatment of retinoblastoma by selective ophthalmic artery infusion. Evomela, a propylene glycol-free formulation of melphalan with improved solubility and stability, has recently been used as an alternative. To compare the safety and efficacy of Evomela with standard-formulation melphalan (SFM) in the treatment of retinoblastoma by selective ophthalmic artery infusion. Methods We performed a retrospective case–control study of patients with retinoblastoma undergoing selective ophthalmic artery infusion with SFM or Evomela at a single institution. Cycle-specific percent tumor regression (CSPTR) was estimated by comparing photos obtained during pretreatment examination under anesthesia (EUA) with those obtained during post-treatment EUA 3–4 weeks later. CSPTR, ocular salvage rates, complication rates, operation times (unadjusted and adjusted for difficulty of ophthalmic artery catheterization), and intraprocedural dose expiration rates were compared between Evomela- and SFM-treated groups. Univariate and multivariate analyses were performed. Results Ninety-seven operations (melphalan: 45; Evomela: 52) for 23 patients with 27 retinoblastomas were studied. The ocular salvage rate was 79% in the SFM-treated group and 69% in the Evomela-treated group. Multivariate regression controlling for tumor grade, patient age, and treatment history revealed no significant differences in ocular salvage rate, CSPTR, complication rates, or operation times. Although the dose expiration rate was higher for the SFM-treated group, the difference was not statistically significant. Notably, there were no ocular or cerebral ischemic complications. Conclusion Evomela has non-inferior safety and efficacy relative to SFM when used for the treatment of retinoblastoma by selective ophthalmic artery infusion.
12 June 2026 in Ophthalmology Science
To evaluate whether hyaloid artery persistence, detected by handheld OCT, is associated with retinopathy of prematurity (ROP) severity. A retrospective cohort study. A total of 162 eyes of preterm infants undergoing ROP screening at a tertiary care neonatal intensive care unit were included. Handheld ultra-widefield OCT images were reviewed at each clinical encounter for the presence or absence of the hyaloid artery. Time to hyaloid artery disappearance was modeled using a Weibull accelerated failure time survival analysis incorporating interval censoring and clustering within subjects. Covariates included ROP severity (mild, moderate, or severe) and gestational age (GA). Leave-one-eye-out cross-validated area under the receiver operating characteristic curves (AUROCs) were calculated to evaluate the discriminative ability of hyaloid regression timing for ROP severity. The primary outcomes were postnatal age (PNA) at hyaloid artery disappearance and AUROC values for No vs. Mild, No vs. Severe, and Mild vs. Severe ROP. The hyaloid artery was detectable by OCT in 152 of 162 (94%) eyes. Compared with eyes with No ROP, hyaloid artery persistence was significantly prolonged in Mild ROP (acceleration factor [AF], 1.354; P = 0.002) and Severe ROP (AF, 1.414; P = 0.006). Median PNA of hyaloid artery disappearance, adjusted for mean GA, was 9.1 weeks for No ROP, 11.7 weeks for Mild ROP, and 12 weeks for Severe ROP. Leave-one-eye-out cross-validated AUROCs demonstrated moderate discrimination between No versus Mild ROP (AUROC = 0.71) and Mild versus Severe ROP (AUROC = 0.76), and strong discrimination between No vs. Severe ROP (AUROC = 0.96). The hyaloid artery is commonly detectable in preterm infants using OCT. Persistence of the hyaloid artery is significantly associated with increasing ROP severity and may serve as a novel, quantifiable biomarker of disease severity and retinal maturation. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
4 September 2023 in The Pediatric Infectious Disease Journal